HUE055175T2 - Az 1-(1-metil-1H-pirazol-4-il)-N-((1R,5S,7S)-9-metil-3-oxa-9-azabiciklo[3.3.1] nonan-7-il)-1H-indol-3-karboxamid kristályos formája - Google Patents

Az 1-(1-metil-1H-pirazol-4-il)-N-((1R,5S,7S)-9-metil-3-oxa-9-azabiciklo[3.3.1] nonan-7-il)-1H-indol-3-karboxamid kristályos formája

Info

Publication number
HUE055175T2
HUE055175T2 HUE15778162A HUE15778162A HUE055175T2 HU E055175 T2 HUE055175 T2 HU E055175T2 HU E15778162 A HUE15778162 A HU E15778162A HU E15778162 A HUE15778162 A HU E15778162A HU E055175 T2 HUE055175 T2 HU E055175T2
Authority
HU
Hungary
Prior art keywords
methyl
nonan
azabicyclo
pyrazol
oxa
Prior art date
Application number
HUE15778162A
Other languages
English (en)
Inventor
Yuxin Zhao
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of HUE055175T2 publication Critical patent/HUE055175T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE15778162A 2014-09-29 2015-09-29 Az 1-(1-metil-1H-pirazol-4-il)-N-((1R,5S,7S)-9-metil-3-oxa-9-azabiciklo[3.3.1] nonan-7-il)-1H-indol-3-karboxamid kristályos formája HUE055175T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462056982P 2014-09-29 2014-09-29

Publications (1)

Publication Number Publication Date
HUE055175T2 true HUE055175T2 (hu) 2021-11-29

Family

ID=54289137

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15778162A HUE055175T2 (hu) 2014-09-29 2015-09-29 Az 1-(1-metil-1H-pirazol-4-il)-N-((1R,5S,7S)-9-metil-3-oxa-9-azabiciklo[3.3.1] nonan-7-il)-1H-indol-3-karboxamid kristályos formája

Country Status (12)

Country Link
US (1) US10329306B2 (hu)
EP (1) EP3201203B1 (hu)
JP (2) JP7055017B2 (hu)
CN (1) CN106795172B (hu)
CA (1) CA2962429C (hu)
DK (1) DK3201203T3 (hu)
ES (1) ES2883295T3 (hu)
HU (1) HUE055175T2 (hu)
MA (1) MA40771B1 (hu)
PL (1) PL3201203T3 (hu)
PT (1) PT3201203T (hu)
WO (1) WO2016053947A1 (hu)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
FI74707C (fi) 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
GB8510752D0 (en) 1985-04-27 1985-06-05 Beecham Group Plc Compounds
EP0498466B1 (en) 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE3722069A1 (de) 1986-08-21 1988-02-25 Toyoda Gosei Kk Signalhornschaltvorrichtung fuer ein steuerrad
JP2765845B2 (ja) 1986-11-21 1998-06-18 グラクソ、グループ、リミテッド 中止症候群の予防の治療薬
IT1226389B (it) * 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
JPH0421681A (ja) 1990-05-14 1992-01-24 Fujisawa Pharmaceut Co Ltd ピロロピリジン誘導体
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
JP3251954B2 (ja) 1990-07-31 2002-01-28 日清ファルマ株式会社 アザビシクロ誘導体
HU211081B (en) 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5149962A (en) 1991-06-03 1992-09-22 Simmonds Precision Products, Inc. Proximity detector using faraday effect and bidirectional transmission
US5344831A (en) 1992-01-31 1994-09-06 Nisshin Flour Milling Co., Ltd. Diazabicyclo derivatives
GB9216154D0 (en) 1992-07-30 1992-09-09 Glaxo Group Ltd Chemical compounds
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
CA2160420A1 (en) 1994-10-20 1996-04-21 Haruhiko Kikuchi 5-ht4 receptor agonists
JP3904254B2 (ja) 1994-10-20 2007-04-11 株式会社日清製粉グループ本社 ５−ｈｔ４受容体作動薬
WO1996012722A1 (fr) 1994-10-20 1996-05-02 Nisshin Flour Milling Co., Ltd. Agoniste des recepteurs 5-ht¿4?
WO2000044743A1 (fr) 1999-01-28 2000-08-03 Nippon Shinyaku Co., Ltd. Derives d'amides et compositions de medicaments
EP1243268A4 (en) 1999-12-14 2003-05-21 Nippon Shinyaku Co Ltd MEDICINAL COMPOSITION
WO2003035625A1 (en) 2001-09-19 2003-05-01 Pharmacia Corporation Substituted indazole compounds for the treatment of inflammation
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
KR101129933B1 (ko) 2002-09-25 2012-03-23 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도
NZ541008A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
US20050234095A1 (en) 2004-03-25 2005-10-20 Wenge Xie Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
UA93348C2 (ru) 2004-03-25 2011-02-10 Меморі Фармас'Ютікалз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение
EP1838669A1 (en) 2005-01-19 2007-10-03 Biolipox AB Indoles useful in the treatment of inflammation
CN101312968A (zh) 2005-09-23 2008-11-26 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
BRPI0707873A2 (pt) 2006-02-15 2011-05-10 Allergan Inc compostos amida, Éster, tioamida e tiol Éster do Ácido indol-3-carboxÍlico carregando grupos arila ou heteroarila tendo atividade biolàgica antagonista de recptor de esfingosina-1-fosfato (s1p)
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
EP2041088B1 (en) 2006-06-28 2014-01-08 Amgen Inc. Glycine transporter-1 inhibitors
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008097930A1 (en) 2007-02-05 2008-08-14 Amira Pharmaceuticals, Inc. Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors
CN101687789A (zh) 2007-02-12 2010-03-31 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
SG183699A1 (en) 2007-08-10 2012-09-27 Lundbeck & Co As H Heteroaryl amide analogues
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
NZ588715A (en) * 2008-05-29 2012-11-30 Albany Molecular Res Inc 5-ht3 receptor modulators, methods of making, and use thereof
TWI429628B (zh) 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5

Also Published As

Publication number Publication date
EP3201203A1 (en) 2017-08-09
US10329306B2 (en) 2019-06-25
US20170233406A1 (en) 2017-08-17
CN106795172B (zh) 2020-07-28
MA40771B1 (fr) 2021-09-30
JP2017529379A (ja) 2017-10-05
CA2962429C (en) 2023-01-03
ES2883295T3 (es) 2021-12-07
PL3201203T3 (pl) 2021-11-22
JP7055017B2 (ja) 2022-04-15
EP3201203B1 (en) 2021-05-19
PT3201203T (pt) 2021-08-09
CN106795172A (zh) 2017-05-31
DK3201203T3 (da) 2021-08-23
CA2962429A1 (en) 2016-04-07
JP2022036978A (ja) 2022-03-08
WO2016053947A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
IL284039A (en) Use of 3-isoxolidinone compounds as selective herbicides
EP3204433B8 (en) Process for the preparation of an alpha-nucleated polypropylene
IL247901A0 (en) Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile
EP3191449A4 (en) Novel compounds as rearranged during transfection (ret) inhibitors
EP3209653A4 (en) Process for the preparation of (r,s)-nicotine
EP3137141A4 (en) Vaporizer
EP3149549A4 (en) Active container
EP3142608A4 (en) Replacement heart valve
EP3142597A4 (en) Spatially improved extented reach ultrasonic toothbrush
EP3177285A4 (en) [5,6]-fused bicyclic antidiabetic compounds
EP3136857A4 (en) Crystalline form of baricitinib
EP3125982A4 (en) Headgear for respiratory interfaces
EP3143153A4 (en) Microbial approach for the production of 5-hydroxytryptophan
EP3177614A4 (en) [7,6]-fused bicyclic antidiabetic compounds
EP3124850A4 (en) Cradle head
EP3119401A4 (en) Cenicriviroc for the treatment of fibrosis
EP3116498A4 (en) Formulation for soft anticholinergic analogs
EP3205458A4 (en) Adsorption nozzle
EP3174393A4 (en) Dual biocide generator
EP3337485A4 (en) CRYSTALLINE FORMS OF IBRUTINIB
EP3113773A4 (en) Crystalline forms of grapiprant
HK1232121A1 (zh) 作為抗氧化治療的富勒烯化合物
EP3359512A4 (en) PROCESS FOR THE PREPARATION OF ORGANIC BROMIDES
IL248027B (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide
EP3221320A4 (en) A process for the preparation of ibrutinib